| Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response M Montesion, K Murugesan, DX Jin, R Sharaf, N Sanchez, A Guria, ... Cancer Discovery 11 (2), 282-292, 2021 | 196 | 2021 |
| Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histologic transformation S Sivakumar, JA Moore, M Montesion, R Sharaf, DI Lin, CI Colón, ... Cancer discovery 13 (7), 1572-1591, 2023 | 67 | 2023 |
| The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling K Umemoto, H Yamamoto, R Oikawa, H Takeda, A Doi, Y Horie, H Arai, ... Journal of the National Cancer Institute 114 (9), 1279-1286, 2022 | 18 | 2022 |
| Genomic profiling of combined hepatocellular cholangiocarcinoma reveals genomics similar to either hepatocellular carcinoma or cholangiocarcinoma K Murugesan, R Sharaf, M Montesion, JA Moore, J Pao, DC Pavlick, ... JCO precision oncology 5, 1285-1296, 2021 | 17 | 2021 |
| Ancestral characterization of the genomic landscape, comprehensive genomic profiling utilization, and treatment patterns may inform disparities in advanced prostate cancer: a … S Sivakumar, JK Lee, JA Moore, J Hopkins, J Newberg, AB Schrock, ... Journal of Clinical Oncology 39 (15_suppl), 5003-5003, 2021 | 12 | 2021 |
| Pan-cancer analysis of copy-number features identifies recurrent signatures and a homologous recombination deficiency biomarker to predict poly (ADP-ribose) polymerase … JA Moore, KT Chen, R Madison, JY Newberg, Z Fleischmann, S Wang, ... JCO Precision Oncology 7, e2300093, 2023 | 10 | 2023 |
| Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation., 2023, 13 S Sivakumar, JA Moore, M Montesion, R Sharaf, DI Lin, CI Colón, ... DOI: https://doi. org/10.1158/2159-8290. CD-22-0620, 1572-1591, 0 | 10 | |
| A novel HRD signature is predictive of FOLFIRINOX benefit in metastatic pancreatic cancer KT Chen, R Madison, J Moore, D Jin, Z Fleischmann, J Newberg, ... The Oncologist 28 (8), 691-698, 2023 | 8 | 2023 |
| Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysis S Sivakumar, JK Lee, JA Moore, J Hopkins, JY Newberg, R Madison, ... The Lancet Digital Health 5 (6), e380-e389, 2023 | 7 | 2023 |
| Development of a pan-cancer algorithm to predict homologous recombination deficiency and sensitivity to PARPi therapy E Antonarakis, J Moore, D Jin, T Chen, J Newberg, Z Fleischmann, ... Cancer Research 82 (12_Supplement), 1249-1249, 2022 | 5 | 2022 |
| Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing SE Trabucco, ES Sokol, SL Maund, JA Moore, GM Frampton, LA Albacker, ... Future Oncology 17 (31), 4171-4183, 2021 | 4 | 2021 |
| 1300p exploration of a novel hrd signature (hrdsig) as a biomarker of first line folfirinox benefit in metastatic pancreatic cancer A Singhi, T Chen, RW Madison, N Bhardwaj, DX Jin, Z Fleischmann, ... Annals of Oncology 33, S1138, 2022 | 3 | 2022 |
| Poor Prognosis among Radiation-Associated Bladder Cancer Is Defined by Clinicogenomic Features NA Wijetunga, KH Gessner, K Kanchi, JA Moore, Z Fleischmann, DX Jin, ... Cancer Research Communications 4 (9), 2320-2334, 2024 | 2 | 2024 |
| Genomic alterations for novel targeted therapies in pancreatobiliary cancers from real-world data. K Umemoto, H Yamamoto, R Oikawa, H Takeda, A Doi, Y Horie, T Ogura, ... Journal of Clinical Oncology 39 (15_suppl), 4124-4124, 2021 | 2 | 2021 |
| Genomic Profiling of Small Intestine Cancers From a Real-World Data Set Identifies Subgroups With Actionable Alterations H Takeda, H Yamamoto, R Oikawa, K Umemoto, H Arai, T Mizukami, ... JCO Precision Oncology 8, e2300425, 2024 | 1 | 2024 |
| The Molecular Landscape of Gastric Cancers for Novel Targeted Therapies from Real-World Genomic Profiling H Yamamoto, H Arai, R Oikawa, K Umemoto, H Takeda, T Mizukami, ... Targeted Oncology, 1-13, 2024 | 1 | 2024 |
| Prediction and Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Cell of Origin (COO) Subtypes Using Genomic Features from Targeted Next-Generation Sequencing SE Trabucco, ES Sokol, JA Moore, S Maund, GM Frampton, VA Miller, ... Blood 132, 1561, 2018 | 1 | 2018 |
| 771P Genomic characterization of advanced endometrial carcinosarcoma: Identification of potentially actionable targets Z Kuang, NA Danziger, JA Moore, DI Lin, G Mangili, S Pignata, ES Sokol, ... Annals of Oncology 34, S523, 2023 | | 2023 |
| Systems and methods for classifying and treating homologous repair deficiency cancers E Sokol, J Moore, J Newberg, JIN Dexter, KT Chen, R Madison US Patent App. 17/899,470, 2023 | | 2023 |
| Comprehensive analysis of 3,600 small cell lung cancer cases reveals rare genetic subtypes and multiple mechanisms of histological transformation S Sivakumar, JA Moore, M Montesion, DI Lin, Z Fleischmann, EM Ebot, ... Cancer Research 83 (7_Supplement), 931-931, 2023 | | 2023 |